Chattem absorbs costs as Sanofi deal nears close
This article was originally published in The Rose Sheet
Executive Summary
The Chattanooga, Tenn., company nudged revenue up 1.9% in fiscal 2009 to $463.3 mil., helped by 4.5% increase in the fourth quarter to $110.2 mil. Full-year net income reached $63.2 mil., a 4.7% dip, the firm said Jan. 28. However, Chattem absorbed a net loss of $4.1 mil. in the three months ended Nov. 30, due to early extinguishment of debt, employee stock option expenses and a non-cash impairment of intangible assets related to the firm's dietary supplement business. Chattem's supplements - including Dexatrim, Garlique and Melatonex - represent about 4% of annual sales. The company did not hold an earnings call to report its financial results, with its acquisition by Sanofi-Aventis near completion (1"The Rose Sheet" Jan. 4, 2010). The French pharma announced Jan. 26 the waiting period under the Hart-Scott Rodino Act passed and the tender offer for all outstanding Chattem shares - at $93.50 each - is set to expire Feb. 8
You may also be interested in...
Marketing In Brief
Gold Bond: Launch of Gold Bond Ultimate Hand Sanitizer Moisturizer targets the 65% of consumers who say they would use hand sanitizer more often if there were a product available that did not dry out their hands, company says. While alcohol-based sanitizers, which make up the bulk of the market, break down skin's protective lipid barrier and facilitate dryness, new offering from Gold Bond kills 99.9% of common germs and bacteria in just 15 seconds with formula that contains seven hydrating agents, including brand's Phospholipid Complex, and no alcohol. "Gold Bond has been working on this for years and has finally created a solution for everyday hand sanitizing health," says Lucas Mininger, marketing manager for Gold Bond. "Consumers in our home-use tests were saying that it felt like a lotion, and they even preferred it to their current moisturizer," he adds. Product can be purchased in 12-oz., 2.7-oz. and 1-oz. tubes for $8.99, $4.49 and $1.49, respectively, at food, drug and mass merchants nationwide, according to Chattem-owned brand, soon to belong to Sanofi-Aventis (1"The Rose Sheet" Feb. 1, 2010, In Brief)
With $1.9 Bil. Bid For Chattem, Sanofi Knocks On Door To U.S. OTC Market
With its $1.9 billion bid for personal-care and over-the-counter drug manufacturer Chattem, French pharmaceutical giant Sanofi-Aventis stands to gain a toehold in the sizeable U.S. consumer health sector and beef up its presence in emerging markets
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.